title: ICUD-EAU International Consultation on Bladder Cancer 2012: Non-muscle-invasive urothelial carcinoma of the bladder.
abstract: BACKGROUND
  Our aim was to present a summary of the Second International Consultation on Bladder Cancer recommendations on the diagnosis and treatment options for non-muscle-invasive urothelial cancer of the bladder (NMIBC) using an evidence-based approach.
  
  
  OBJECTIVE
  To critically review the recent data on the management of NMIBC to arrive at a general consensus.
  
  
  METHODS
  A detailed Medline analysis was performed for original articles addressing the treatment of NMIBC with regard to diagnosis, surgery, intravesical chemotherapy, and follow-up. Proceedings from the last 5 yr of major conferences were also searched.
  
  
  RESULTS
  The major findings are presented in an evidence-based fashion. We analyzed large retrospective and prospective studies.
  
  
  CONCLUSIONS
  Urothelial cancer of the bladder staged Ta, T1, and carcinoma in situ (CIS), also indicated as NMIBC, poses greatly varying but uniformly demanding challenges to urologic care. On the one hand, the high recurrence rate and low progression rate with Ta low-grade demand risk-adapted treatment and surveillance to provide thorough care while minimizing treatment-related burden. On the other hand, the propensity of Ta high-grade, T1, and CIS to progress demands intense care and timely consideration of radical cystectomy.
authors.affiliation: Department of Urology and Pediatric Urology, Julius-Maximilians-University Medical Center, Würzburg, Germany.
authors.forename: Maximilian
authors.initials: M
authors.lastname: Burger
authors.forename: Willem
authors.initials: W
authors.lastname: Oosterlinck
authors.forename: Badrinath
authors.initials: B
authors.lastname: Konety
authors.forename: Sam
authors.initials: S
authors.lastname: Chang
authors.forename: Sigurdur
authors.initials: S
authors.lastname: Gudjonsson
authors.forename: Raj
authors.initials: R
authors.lastname: Pruthi
authors.forename: Mark
authors.initials: M
authors.lastname: Soloway
authors.forename: Eduardo
authors.initials: E
authors.lastname: Solsona
authors.forename: Paul
authors.initials: P
authors.lastname: Sved
authors.forename: Marko
authors.initials: M
authors.lastname: Babjuk
authors.forename: Maurizio A
authors.initials: MA
authors.lastname: Brausi
authors.forename: Christopher
authors.initials: C
authors.lastname: Cheng
authors.forename: Eva
authors.initials: E
authors.lastname: Comperat
authors.forename: Colin
authors.initials: C
authors.lastname: Dinney
authors.forename: Wolfgang
authors.initials: W
authors.lastname: Otto
authors.forename: Jay
authors.initials: J
authors.lastname: Shah
authors.forename: Joachim
authors.initials: J
authors.lastname: Thürof
authors.forename: J Alfred
authors.initials: JA
authors.lastname: Witjes
mesh_terms: D000283:Administration, Intravesical; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D001500:BCG Vaccine / Q000008:administration & dosage*; D002278:Carcinoma in Situ / Q000175:diagnosis* / Q000473:pathology / Q000628:therapy*; D015653:Cystectomy / Q000592:standards*; D018450:Disease Progression; D006801:Humans; D060787:Neoplasm Grading / Q000592:standards; D009361:Neoplasm Invasiveness; D009364:Neoplasm Recurrence, Local; D009367:Neoplasm Staging / Q000592:standards; D016896:Treatment Outcome; D001749:Urinary Bladder Neoplasms / Q000175:diagnosis* / Q000473:pathology / Q000628:therapy*; D019459:Urothelium / Q000473:pathology / Q000601:surgery*
chemical_list: D000970:Antineoplastic Agents; D001500:BCG Vaccine